High risk and low prevalence diseases: Metformin toxicities.
Am J Emerg Med
; 72: 107-112, 2023 10.
Article
em En
| MEDLINE
| ID: mdl-37517113
ABSTRACT
INTRODUCTION:
Metformin toxicity is a rare but serious condition that carries with it a high rate of morbidity and mortality.OBJECTIVE:
This review highlights the pearls and pitfalls of metformin toxicity, including diagnosis, initial resuscitation, and management in the emergency department (ED) based on current evidence.DISCUSSION:
Metformin is a common medication used for treatment of diabetes mellitus. Metformin toxicity is a spectrum of conditions that may be differentiated into three subgroups metformin-associated lactic acidosis (MALA), metformin-induced lactic acidosis (MILA), and metformin-unrelated lactic acidosis (MULA). MILA is a condition found predominantly in patients chronically taking metformin or those with large acute overdoses. Conversely, MULA occurs in patients on metformin but with a critical illness stemming from a separate cause. MALA is rare but the most severe form, with mortality rates that reach 50%. Differentiating these entities is difficult in the ED setting without obtaining metformin levels. Patients with metformin toxicity present with nonspecific gastrointestinal symptoms and vital sign abnormalities. Laboratory analysis will reveal a high lactate with anion gap metabolic acidosis. Patients presenting with elevated lactate levels in the setting of metformin use should be considered at risk for the most severe form, MALA. Patients with MALA require aggressive treatment with intravenous fluids, treatment of any concomitant condition, and early consideration of hemodialysis, along with specialist consultation such as nephrology and toxicology.CONCLUSIONS:
An understanding of metformin toxicity can assist emergency clinicians in diagnosing and managing this potentially deadly disease.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Acidose Láctica
/
Diabetes Mellitus Tipo 2
/
Metformina
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos